Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 2007
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which markets contact lenses, and CooperSurgical (CSI), which markets medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Sales | $219.4 million | $205.7 million |
| Gross Profit | $129.9 million | $129.2 million |
| Gross Margin | 59.2% | 62.8% |
| Operating Income | $15.8 million | $33.7 million |
| Net Income | $5.3 million | $18.0 million |
| Diluted EPS | $0.12 | $0.39 |
| Cash from Operations | $0.8 million | $29.3 million |
| Total Debt | $853.7 million | $742.7 million |
| Cash and Equivalents | $23.5 million | $8.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% year-over-year, driven by a 19% increase in CSI sales and a 5% increase in CVI sales. Constant currency growth was 4%.
- Profitability Decline: Operating income decreased 53% to $15.8 million. This decline was primarily due to increased expenses related to restructuring, integration, and litigation.
- Margin Compression: Gross margin decreased from 63% to 59%. CVI margins were impacted by manufacturing inefficiencies related to new silicone hydrogel products and unfavorable foreign currency. CSI margins improved to 60% from 57%.
- Expense Increases:
- Selling, General, and Administrative (SG&A) expenses rose 15% to $97.5 million.
- Research and Development (R&D) expenses surged 87% to $11.1 million, including a $4.2 million write-off of acquired in-process R&D.
- Restructuring costs increased 39% to $1.9 million.
- Cash Flow: Operating cash flow dropped significantly to $0.8 million from $29.3 million, largely due to an $83.5 million increase in working capital (inventory build-up and receivables) and a decrease in current liabilities.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Product Strategy: The Company is focused on launching silicone hydrogel contact lenses, a major industry trend. While initial customer reaction is favorable, the Company faces manufacturing ramp-up costs and efficiency challenges.
- Capital Expenditures: Expected to be approximately $160 million for fiscal 2007, primarily for manufacturing expansion, distribution consolidation, and IT systems.
- Debt Refinancing: On January 31, 2007, the Company refinanced its credit facility, issuing $350 million in 7.125% Senior Notes due 2015 and establishing a $650 million revolving credit facility. This extended maturities and lowered overall pricing.
Risks and Contingencies
- Legal Proceedings:
- Securities Litigation: A consolidated class action lawsuit alleges improper accounting for the Ocular Sciences acquisition and inflated earnings guidance. A hearing on the motion to dismiss is scheduled for May 2007.
- Patent Litigation: Ongoing disputes with Bausch & Lomb and CIBA Vision regarding contact lens patents. The Company intends to vigorously defend these matters.
- Tax Litigation: The IRS has asserted a deficiency of $44.8 million plus penalties regarding transfer pricing for the years 1999-2001. The Company contests this and does not expect a material adverse effect.
- Integration Risks: The Company is integrating the Ocular Sciences acquisition, with total restructuring costs estimated at $45-$50 million. Manufacturing inefficiencies associated with new products are expected to continue through the year.
- Market Risks: Exposure to foreign currency fluctuations and interest rate changes on variable-rate debt, though hedging strategies are in place.
Investor Verification Checklist
- Restructuring Costs: Verify the timeline and total cost of the Ocular Sciences integration plan ($45-$50 million estimate) and its impact on future margins.
- Silicone Hydrogel Ramp-up: Monitor the Company's ability to achieve manufacturing efficiencies and cost targets for new silicone hydrogel products to restore CVI margins.
- Legal Outcomes: Track the status of the securities class action lawsuit and patent litigation with CIBA Vision and Bausch & Lomb for potential settlement costs or injunctions.
- Debt Covenants: Confirm continued compliance with the new credit facility covenants, specifically the Interest Coverage Ratio (currently 6.92:1) and Total Leverage Ratio (currently 3.56:1).
- Working Capital Management: Assess the sustainability of the increased inventory levels (8.3 months on hand) and receivables in light of the significant drop in operating cash flow.